BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung SN, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Schwartz ME, Llovet JM. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011;140:1501-12.e2. [PMID: 21320499 DOI: 10.1053/j.gastro.2011.02.006] [Cited by in Crossref: 254] [Cited by in F6Publishing: 235] [Article Influence: 25.4] [Reference Citation Analysis]
Number Citing Articles
1 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Truant S, Boleslawski E, Duhamel A, Bouras AF, Louvet A, Febvay C, Leteurtre E, Huet G, Zerbib P, Dharancy S. Tumor size of hepatocellular carcinoma in noncirrhotic liver: a controversial predictive factor for outcome after resection. Eur J Surg Oncol. 2012;38:1189-1196. [PMID: 22863304 DOI: 10.1016/j.ejso.2012.07.112] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
3 Ye K, Chang S, Li J, Li X, Zhou Y, Wang Z. A functional and protein-protein interaction analysis of neuroepithelial cell transforming gene 1 in hepatocellular carcinoma. Tumor Biol 2014;35:11219-27. [DOI: 10.1007/s13277-014-2454-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Qiu L, Zhan K, Malale K, Wu X, Mei Z. Transcriptomic profiling of peroxisome-related genes reveals a novel prognostic signature in hepatocellular carcinoma. Genes & Diseases 2020. [DOI: 10.1016/j.gendis.2020.04.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Athreya AP, Lazaridis KN. Discovery and Opportunities With Integrative Analytics Using Multiple-Omics Data. Hepatology 2021;74:1081-7. [PMID: 33539039 DOI: 10.1002/hep.31733] [Reference Citation Analysis]
6 Zhou L, Liao Y, Yin P, Zeng Z, Li J, Lu X, Zheng L, Xu G. Metabolic profiling study of early and late recurrence of hepatocellular carcinoma based on liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;966:163-170. [PMID: 24582150 DOI: 10.1016/j.jchromb.2014.01.057] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
7 Heuman DM, Gilles HS, Solomon C, Bajaj JS. Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? No. Eur J Intern Med. 2012;23:37-39. [PMID: 22153529 DOI: 10.1016/j.ejim.2011.09.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
8 Le Y, Kan A, Li QJ, He MK, Chen HL, Shi M. NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma. Cancer Cell Int 2019;19:228. [PMID: 31516385 DOI: 10.1186/s12935-019-0949-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
9 Sherman M, Burak K, Maroun J, Metrakos P, Knox JJ, Myers RP, Guindi M, Porter G, Kachura JR, Rasuli P, Gill S, Ghali P, Chaudhury P, Siddiqui J, Valenti D, Weiss A, Wong R. Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma. Curr Oncol 2011;18:228-40. [PMID: 21980250 DOI: 10.3747/co.v18i5.952] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
10 Liu Y, Zhang X, Zhou S, Shi J, Xu Y, He J, Lin F, Wei A, Zhou L, Chen Z. Knockdown of Golgi phosphoprotein 73 blocks the trafficking of matrix metalloproteinase-2 in hepatocellular carcinoma cells and inhibits cell invasion. J Cell Mol Med 2019;23:2399-409. [PMID: 30677226 DOI: 10.1111/jcmm.14055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
11 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3191] [Article Influence: 404.7] [Reference Citation Analysis]
12 Villanueva A, Hoshida Y. Depicting the role of TP53 in hepatocellular carcinoma progression. J Hepatol. 2011;55:724-725. [PMID: 21616106 DOI: 10.1016/j.jhep.2011.03.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
13 Su J, Zhang Y, Su H, Zhang C, Li W. A recurrence model for laryngeal cancer based on SVM and gene function clustering. Acta Otolaryngol 2017;137:557-62. [PMID: 27809638 DOI: 10.1080/00016489.2016.1247984] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
14 Pedica F, Ruzzenente A, Bagante F, Capelli P, Cataldo I, Pedron S, Iacono C, Chilosi M, Scarpa A, Brunelli M. A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse. PLoS One. 2013;8:e68203. [PMID: 23874541 DOI: 10.1371/journal.pone.0068203] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
15 Xiao S, Tang H, Bai Y, Zou R, Ren Z, Wu X, Shi Z, Lan S, Liu W, Wu T, Zhang C, Wang L. Swertiamarin suppresses proliferation, migration, and invasion of hepatocellular carcinoma cells <em>via</em> negative regulation of FRAT1. Eur J Histochem 2020;64. [PMID: 33131270 DOI: 10.4081/ejh.2020.3169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Passman AM, Low J, London R, Tirnitz-Parker JE, Miyajima A, Tanaka M, Strick-Marchand H, Darlington GJ, Finch-Edmondson M, Ochsner S, Zhu C, Whelan J, Callus BA, Yeoh GC. A Transcriptomic Signature of Mouse Liver Progenitor Cells. Stem Cells Int 2016;2016:5702873. [PMID: 27777588 DOI: 10.1155/2016/5702873] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wang D, Hu X, Xiao L, Long G, Yao L, Wang Z, Zhou L. Prognostic Nutritional Index and Systemic Immune-Inflammation Index Predict the Prognosis of Patients with HCC. J Gastrointest Surg 2021;25:421-7. [PMID: 32026332 DOI: 10.1007/s11605-019-04492-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
18 Pedro B, Rupji M, Dwivedi B, Kowalski J, Konen JM, Owonikoko TK, Ramalingam SS, Vertino PM, Marcus AI. Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q. Cancer 2020;126:3140-50. [PMID: 32315457 DOI: 10.1002/cncr.32903] [Reference Citation Analysis]
19 Yasui Y, Kudo A, Kurosaki M, Matsuda S, Muraoka M, Tamaki N, Suzuki S, Hosokawa T, Ueda K, Matsunaga K, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Tanaka S, Asahina Y, Enomoto N, Arii S, Izumi N. Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study. Oncology. 2014;86:53-62. [PMID: 24401597 DOI: 10.1159/000356643] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
20 Chang WJ, Du Y, Zhao X, Ma LY, Cao GW. Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol 2014;20:4586-96. [PMID: 24782611 DOI: 10.3748/wjg.v20.i16.4586] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 90] [Article Influence: 15.8] [Reference Citation Analysis]
21 Zhu HT, Dong QZ, Sheng YY, Wei JW, Wang G, Zhou HJ, Ren N, Jia HL, Ye QH, Qin LX. MicroRNA-29a-5p is a novel predictor for early recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. PLoS One 2012;7:e52393. [PMID: 23285022 DOI: 10.1371/journal.pone.0052393] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
22 Zhang W, Zhangyuan G, Wang F, Zhang H, Yu D, Wang J, Jin K, Yu W, Liu Y, Sun B. High preoperative serum globulin in hepatocellular carcinoma is a risk factor for poor survival. J Cancer 2019;10:3494-500. [PMID: 31293654 DOI: 10.7150/jca.29499] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
23 Rhee H, Kim H, Park YN. Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression. Liver Cancer 2020;9:663-81. [PMID: 33442539 DOI: 10.1159/000510522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Martinez-quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-carunchio L, Solé M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models. Gastroenterology 2016;151:1192-205. [DOI: 10.1053/j.gastro.2016.09.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 12.4] [Reference Citation Analysis]
25 Torrecilla S, Sia D, Harrington AN, Zhang Z, Cabellos L, Cornella H, Moeini A, Camprecios G, Leow WQ, Fiel MI, Hao K, Bassaganyas L, Mahajan M, Thung SN, Villanueva A, Florman S, Schwartz ME, Llovet JM. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. J Hepatol. 2017;67:1222-1231. [PMID: 28843658 DOI: 10.1016/j.jhep.2017.08.013] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 14.0] [Reference Citation Analysis]
26 Yan P, Huang Z, Mou T, Luo Y, Liu Y, Zhou B, Cao Z, Wu Z. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence. BMC Cancer 2021;21:436. [PMID: 33879119 DOI: 10.1186/s12885-021-08173-0] [Reference Citation Analysis]
27 Govaere O, Roskams T. Pathogenesis and prognosis of hepatocellular carcinoma at the cellular and molecular levels. Clin Liver Dis. 2015;19:261-276. [PMID: 25921662 DOI: 10.1016/j.cld.2015.01.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
28 Yang L, Wang X, Xu J, Wen Y, Zhang M, Lu J, Wang R, Sun X. Integrated transcriptomic and proteomic analyses reveal ɑ-lipoic acid-regulated cell proliferation via Grb2-mediated signalling in hepatic cancer cells. J Cell Mol Med 2018;22:2981-92. [PMID: 29575431 DOI: 10.1111/jcmm.13447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zhu C, Ho YJ, Salomao MA, Dapito DH, Bartolome A, Schwabe RF, Lee JS, Lowe SW, Pajvani UB. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features. J Hepatol 2021;74:613-26. [PMID: 33038431 DOI: 10.1016/j.jhep.2020.09.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
30 Liu J, Dang H, Wang XW. The significance of intertumor and intratumor heterogeneity in liver cancer. Exp Mol Med. 2018;50:e416. [PMID: 29303512 DOI: 10.1038/emm.2017.165] [Cited by in Crossref: 65] [Cited by in F6Publishing: 47] [Article Influence: 21.7] [Reference Citation Analysis]
31 Maggs JRL, Suddle AR, Aluvihare V, Heneghan MA. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:1113-34. [DOI: 10.1111/j.1365-2036.2012.05072.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
32 Weng J, Atyah M, Zhou C, Ren N. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma. Clin Exp Med 2020;20:329-37. [PMID: 32239299 DOI: 10.1007/s10238-020-00620-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
33 Sun L, Li K, Liu G, Xu Y, Zhang A, Lin D, Zhang H, Zhao X, Jin B, Li N, Zhang Y. Distinctive pattern of AHNAK methylation level in peripheral blood mononuclear cells and the association with HBV-related liver diseases. Cancer Med 2018;7:5178-86. [PMID: 30259695 DOI: 10.1002/cam4.1778] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Zhang H, Han J, Xing H, Li Z, Schwartz ME, Zhou Y, Chen T, Wang H, Gu W, Lau WY, Wu H, Wu M, Shen F, Yang T. Sex difference in recurrence and survival after liver resection for hepatocellular carcinoma: A multicenter study. Surgery 2019;165:516-24. [DOI: 10.1016/j.surg.2018.08.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
35 Huang W, Yu D, Wang M, Han Y, Lin J, Wei D, Cai J, Li B, Chen P, Zhang X. ITGBL1 promotes cell migration and invasion through stimulating the TGF-β signalling pathway in hepatocellular carcinoma. Cell Prolif 2020;53:e12836. [PMID: 32537856 DOI: 10.1111/cpr.12836] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
36 Liu XY, Xu JF. Liver resection for young patients with large hepatocellular carcinoma: a single center experience from China. World J Surg Oncol 2014;12:175. [PMID: 24894964 DOI: 10.1186/1477-7819-12-175] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
37 Sun X, Zhu H, Cao R, Zhang J, Wang X. BACH1 is transcriptionally inhibited by TET1 in hepatocellular carcinoma in a microRNA-34a-dependent manner to regulate autophagy and inflammation. Pharmacol Res 2021;169:105611. [PMID: 33878446 DOI: 10.1016/j.phrs.2021.105611] [Reference Citation Analysis]
38 Zou H, Liao M, Xu W, Yao R, Liao W. Data mining of the expression and regulatory role of BCAT1 in hepatocellular carcinoma. Oncol Lett 2019;18:5879-88. [PMID: 31788061 DOI: 10.3892/ol.2019.10932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol. 2015;7:139-149. [PMID: 25729470 DOI: 10.4254/wjh.v7.i2.139] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
40 Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2021:S0168-8278(21)00326-3. [PMID: 33992698 DOI: 10.1016/j.jhep.2021.04.049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Fuks D, Dokmak S, Paradis V, Diouf M, Durand F, Belghiti J. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: An intention-to-treat analysis. Hepatology. 2012;55:132-140. [PMID: 21932387 DOI: 10.1002/hep.24680] [Cited by in Crossref: 173] [Cited by in F6Publishing: 153] [Article Influence: 19.2] [Reference Citation Analysis]
42 Revill K, Wang T, Lachenmayer A, Kojima K, Harrington A, Li J, Hoshida Y, Llovet JM, Powers S. Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology 2013;145:1424-35.e1-25. [PMID: 24012984 DOI: 10.1053/j.gastro.2013.08.055] [Cited by in Crossref: 122] [Cited by in F6Publishing: 107] [Article Influence: 15.3] [Reference Citation Analysis]
43 Du Y, Cao GW. Challenges of incorporating gene expression data to predict HCC prognosis in the age of systems biology. World J Gastroenterol 2012;18:3941-4. [PMID: 22912544 DOI: 10.3748/wjg.v18.i30.3941] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
44 Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Machaca MP, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Fauda M, McCormack L, Gadano A, Boin IS, García JHP, Silva M. Results of Liver Transplantation for Hepatocellular Carcinoma in a Multicenter Latin American Cohort Study. Ann Hepatol 2018;17:256-67. [PMID: 29469048 DOI: 10.5604/01.3001.0010.8648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Bassaganyas L, Pinyol R, Esteban-Fabró R, Torrens L, Torrecilla S, Willoughby CE, Franch-Expósito S, Vila-Casadesús M, Salaverria I, Montal R, Mazzaferro V, Camps J, Sia D, Llovet JM. Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. Clin Cancer Res 2020;26:6350-61. [PMID: 32873569 DOI: 10.1158/1078-0432.CCR-20-1497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
46 Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J. High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. Transl Oncol 2019;12:256-68. [PMID: 30439626 DOI: 10.1016/j.tranon.2018.10.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
47 Burska AN, Roget K, Blits M, Soto Gomez L, van de Loo F, Hazelwood LD, Verweij CL, Rowe A, Goulielmos GN, van Baarsen LG, Ponchel F. Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics J 2014;14:93-106. [PMID: 24589910 DOI: 10.1038/tpj.2013.48] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
48 Gao H, Hao Y, Zhou X, Li H, Liu F, Zhu H, Song X, Niu Z, Ni Q, Chen MS, Lu J. Prognostic value of glucose transporter 3 expression in hepatocellular carcinoma. Oncol Lett 2020;19:691-9. [PMID: 31885715 DOI: 10.3892/ol.2019.11191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
49 Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, Rodriguez-Carunchio L, Solé M, Thung S, Stanger BZ. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology. 2012;143:1660-1669.e7. [PMID: 22974708 DOI: 10.1053/j.gastro.2012.09.002] [Cited by in Crossref: 193] [Cited by in F6Publishing: 172] [Article Influence: 21.4] [Reference Citation Analysis]
50 Dodson RM, He J, Pawlik TM. Resection and transplantation for hepatocellular carcinoma: factors influencing surgical options. Future Oncology 2014;10:587-607. [DOI: 10.2217/fon.13.225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
51 Kojima K, April C, Canasto-Chibuque C, Chen X, Deshmukh M, Venkatesh A, Tan PS, Kobayashi M, Kumada H, Fan JB. Transcriptome profiling of archived sectioned formalin-fixed paraffin-embedded (AS-FFPE) tissue for disease classification. PLoS One. 2014;9:e86961. [PMID: 24498002 DOI: 10.1371/journal.pone.0086961] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
52 Xie L, Li M, Liu D, Wang X, Wang P, Dai H, Yang W, Liu W, Hu X, Zhao M. Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway. Molecules 2019;24:E393. [PMID: 30678274 DOI: 10.3390/molecules24030393] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
53 Kwee SA, Tiirikainen M, Sato MM, Acoba JD, Wei R, Jia W, Le Marchand L, Wong LL. Transcriptomics Associates Molecular Features with 18F-Fluorocholine PET/CT Imaging Phenotype and Its Potential Relationship to Survival in Hepatocellular Carcinoma. Cancer Res 2019;79:1696-704. [PMID: 30760520 DOI: 10.1158/0008-5472.CAN-18-3837] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
54 Vibert E, Ishizawa T. Hepatocellular carcinoma: Western and Eastern surgeons' points of view. J Visc Surg 2012;149:e302-6. [PMID: 22694943 DOI: 10.1016/j.jviscsurg.2012.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
55 Hesketh RL, Zhu AX, Oklu R. Hepatocellular carcinoma: can circulating tumor cells and radiogenomics deliver personalized care? Am J Clin Oncol 2015;38:431-6. [PMID: 25238287 DOI: 10.1097/COC.0000000000000123] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
56 Moni MA, Liò P. comoR: a software for disease comorbidity risk assessment. J Clin Bioinforma 2014;4:8. [PMID: 25045465 DOI: 10.1186/2043-9113-4-8] [Cited by in Crossref: 52] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
57 Nault J, Martin Y, Caruso S, Hirsch TZ, Bayard Q, Calderaro J, Charpy C, Copie‐bergman C, Ziol M, Bioulac‐sage P, Couchy G, Blanc J, Nahon P, Amaddeo G, Ganne‐carrie N, Morcrette G, Chiche L, Duvoux C, Faivre S, Laurent A, Imbeaud S, Rebouissou S, Llovet JM, Seror O, Letouzé E, Zucman‐rossi J. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology 2020;71:164-82. [DOI: 10.1002/hep.30811] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 47.0] [Reference Citation Analysis]
58 Cescon M, Bertuzzo VR, Ercolani G, Ravaioli M, Odaldi F, Pinna AD. Liver transplantation for hepatocellular carcinoma: role of inflammatory and immunological state on recurrence and prognosis. World J Gastroenterol. 2013;19:9174-9182. [PMID: 24409045 DOI: 10.3748/wjg.v19.i48.9174] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
59 Jiang M, Zeng Q, Dai S, Liang H, Dai F, Xie X, Lu K, Gao C. Comparative analysis of hepatocellular carcinoma and cirrhosis gene expression profiles. Mol Med Rep 2017;15:380-6. [PMID: 27959423 DOI: 10.3892/mmr.2016.6021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
60 Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L, Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Solé M, Domingo-Domenech J, Villanueva A, Llovet JM. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut 2017;66:530-40. [PMID: 26658144 DOI: 10.1136/gutjnl-2015-309501] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 14.7] [Reference Citation Analysis]
61 Mu D, Qin F, Li B, Zhou Q. Identification of the Sixth Complement Component as Potential Key Genes in Hepatocellular Carcinoma via Bioinformatics Analysis. Biomed Res Int 2020;2020:7042124. [PMID: 33083480 DOI: 10.1155/2020/7042124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, Gaston Mathe Y, Laurent C, Laurent A, Bioulac-Sage P, Calderaro J, Zucman-Rossi J. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut. 2015;64:820-829. [PMID: 25021421 DOI: 10.1136/gutjnl-2013-306228] [Cited by in Crossref: 86] [Cited by in F6Publishing: 72] [Article Influence: 12.3] [Reference Citation Analysis]
63 Hernandez-Meza G, von Felden J, Gonzalez-Kozlova EE, Garcia-Lezana T, Peix J, Portela A, Craig AJ, Sayols S, Schwartz M, Losic B, Mazzaferro V, Esteller M, Llovet JM, Villanueva A. DNA Methylation Profiling of Human Hepatocarcinogenesis. Hepatology 2021;74:183-99. [PMID: 33237575 DOI: 10.1002/hep.31659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
64 Li J, Liao Y, Suo L, Zhu P, Chen X, Dang W, Liao M, Qin L, Liao W. A novel prognostic index-neutrophil times γ-glutamyl transpeptidase to lymphocyte ratio (NγLR) predicts outcome for patients with hepatocellular carcinoma. Sci Rep 2017;7:9229. [PMID: 28835713 DOI: 10.1038/s41598-017-09696-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
65 Park YK, Song SK, Kim BW, Park SK, Lee JI, Lim SS, Wang HJ. Conditional Survival Analysis Demonstrates that Recurrence Risk of Surgically Treated Hepatocellular Carcinoma Evolves with Time. J Gastrointest Surg 2017;21:1237-44. [PMID: 28536805 DOI: 10.1007/s11605-017-3437-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Piñero F, Costa P, Boteon YL, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Padilla Machaca M, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Podestá LG, Mccormack L, Gadano A, Boin ISF, García P, Silva M. A changing etiologic scenario in liver transplantation for hepatocellular carcinoma in a multicenter cohort study from Latin America. Clinics and Research in Hepatology and Gastroenterology 2018;42:443-52. [DOI: 10.1016/j.clinre.2018.03.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
67 Lué A, Serrano MT, Bustamante FJ, Iñarrairaegui M, Arenas JI, Testillano M, Lorente S, Gil C, de la Torre M, Gomez A, Sangro B. Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. Oncotarget 2017;8:103077-86. [PMID: 29262546 DOI: 10.18632/oncotarget.21528] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
68 Lim HY, Sohn I, Deng S, Lee J, Jung SH, Mao M, Xu J, Wang K, Shi S, Joh JW, Choi YL, Park CK. Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling. Ann Surg Oncol. 2013;20:3747-3753. [PMID: 23800896 DOI: 10.1245/s10434-013-3070-y] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 7.9] [Reference Citation Analysis]
69 Tsai LY, Chang YW, Lee MC, Chang YC, Hwang PI, Huang YS, Cheng CF. Biphasic and Stage-Associated Expression of CPEB4 in Hepatocellular Carcinoma. PLoS One 2016;11:e0155025. [PMID: 27158894 DOI: 10.1371/journal.pone.0155025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
70 Sia D, Villanueva A, Friedman SL, Llovet JM. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology. 2017;152:745-761. [PMID: 28043904 DOI: 10.1053/j.gastro.2016.11.048] [Cited by in Crossref: 373] [Cited by in F6Publishing: 316] [Article Influence: 74.6] [Reference Citation Analysis]
71 Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844-855. [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627] [Cited by in Crossref: 790] [Cited by in F6Publishing: 739] [Article Influence: 112.9] [Reference Citation Analysis]
72 Lavi O, Skinner J, Gottesman MM. Network features suggest new hepatocellular carcinoma treatment strategies. BMC Syst Biol. 2014;8:88. [PMID: 25070212 DOI: 10.1186/s12918-014-0088-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
73 Marjanovic ND, Hofree M, Chan JE, Canner D, Wu K, Trakala M, Hartmann GG, Smith OC, Kim JY, Evans KV, Hudson A, Ashenberg O, Porter CBM, Bejnood A, Subramanian A, Pitter K, Yan Y, Delorey T, Phillips DR, Shah N, Chaudhary O, Tsankov A, Hollmann T, Rekhtman N, Massion PP, Poirier JT, Mazutis L, Li R, Lee JH, Amon A, Rudin CM, Jacks T, Regev A, Tammela T. Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell 2020;38:229-246.e13. [PMID: 32707077 DOI: 10.1016/j.ccell.2020.06.012] [Cited by in Crossref: 44] [Cited by in F6Publishing: 27] [Article Influence: 44.0] [Reference Citation Analysis]
74 Pogribny IP, Rusyn I. Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. Cancer Lett. 2014;342:223-230. [PMID: 22306342 DOI: 10.1016/j.canlet.2012.01.038] [Cited by in Crossref: 109] [Cited by in F6Publishing: 103] [Article Influence: 12.1] [Reference Citation Analysis]
75 Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol. 2014;184:574-583. [PMID: 24388934 DOI: 10.1016/j.ajpath.2013.10.028] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
76 Ozdemir B, Abd-Almageed W, Roessler S, Wang XW. iSubgraph: integrative genomics for subgroup discovery in hepatocellular carcinoma using graph mining and mixture models. PLoS One 2013;8:e78624. [PMID: 24223834 DOI: 10.1371/journal.pone.0078624] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
77 von Felden J, Heim D, Schulze K, Krech T, Ewald F, Nashan B, Lohse AW, Wege H. High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. BMC Cancer 2017;17:60. [PMID: 28100188 DOI: 10.1186/s12885-017-3053-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
78 Nakanishi H, Kurosaki M, Tsuchiya K, Yasui Y, Higuchi M, Yoshida T, Komiyama Y, Takaura K, Hayashi T, Kuwabara K, Nakakuki N, Takada H, Ueda M, Tamaki N, Suzuki S, Itakura J, Takahashi Y, Izumi N. Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. Liver Cancer 2016;5:257-68. [PMID: 27781198 DOI: 10.1159/000449337] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
79 Tang Z. A simple inflammation marker predicts liver cancer prognosis. Nat Rev Gastroenterol Hepatol 2011;8:367-8. [DOI: 10.1038/nrgastro.2011.105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 Chai H, Li ZN, Meng DY, Xia LY, Liang Y. A new semi-supervised learning model combined with Cox and SP-AFT models in cancer survival analysis. Sci Rep 2017;7:13053. [PMID: 29026100 DOI: 10.1038/s41598-017-13133-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
81 Aziz S, Sey M, Marotta P, Driman D, Parfitt J, Teriaky A, Brahmania M, Skaro A, Qumosani K. Recurrent Hepatocellular Carcinoma After Liver Transplantation: Validation of a Pathologic Risk Score on Explanted Livers to Predict Recurrence. Transplant Proc 2021;53:1975-9. [PMID: 34272052 DOI: 10.1016/j.transproceed.2021.05.007] [Reference Citation Analysis]
82 Villanueva A, Llovet JM. Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. Hepatology 2012;56:2416-9. [PMID: 23212778 DOI: 10.1002/hep.26124] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
83 Teufel A, Marquardt JU, Galle PR. Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration. J Hepatol. 2012;56:279-281. [PMID: 21782765 DOI: 10.1016/j.jhep.2011.05.035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
84 Zhang T, Guo J, Gu J, Chen K, Wang Z, Li H, Wang G, Wang J. KIAA0101 is a novel transcriptional target of FoxM1 and is involved in the regulation of hepatocellular carcinoma microvascular invasion by regulating epithelial-mesenchymal transition. J Cancer 2019;10:3501-16. [PMID: 31293655 DOI: 10.7150/jca.29490] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
85 Wang D, Xu Y, Goldstein JB, Ye K, Hu X, Xiao L, Li L, Chang L, Guan Y, Long G, He Q, Yi X, Zhang J, Wang Z, Xia X, Zhou L. Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma. Liver Int 2020;40:1997-2007. [PMID: 32279416 DOI: 10.1111/liv.14463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
86 Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64:S84-S101. [PMID: 27084040 DOI: 10.1016/j.jhep.2016.02.021] [Cited by in Crossref: 330] [Cited by in F6Publishing: 303] [Article Influence: 82.5] [Reference Citation Analysis]
87 Bei C, Zhang Y, Wei R, Zhu X, Wang Z, Zeng W, Chen Q, Tan S. Clinical significance of CMTM4 expression in hepatocellular carcinoma. Onco Targets Ther 2017;10:5439-43. [PMID: 29180877 DOI: 10.2147/OTT.S149786] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
88 Chen JY, Liu LP, Xu JF. Decrease of RBM4 indicates poor prognosis in patients with hepatocellular carcinoma after hepatectomy. Onco Targets Ther. 2017;10:339-345. [PMID: 28138257 DOI: 10.2147/ott.s125250] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
89 Wang L, Zhang Z, Li Y, Wan Y, Xing B. Integrated bioinformatic analysis of RNA binding proteins in hepatocellular carcinoma. Aging (Albany NY) 2020;13:2480-505. [PMID: 33411682 DOI: 10.18632/aging.202281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Huang C, Wang Y, Liu S, Ding G, Liu W, Zhou J, Kuang M, Ji Y, Kondo T, Fan J. Quantitative proteomic analysis identified paraoxonase 1 as a novel serum biomarker for microvascular invasion in hepatocellular carcinoma. J Proteome Res 2013;12:1838-46. [PMID: 23442176 DOI: 10.1021/pr3011815] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
91 Ang SF, Ng ES, Li H, Ong YH, Choo SP, Ngeow J, Toh HC, Lim KH, Yap HY, Tan CK, Ooi LL, Cheow PC, Chung AY, Chow PK, Foo KF, Tan MH. The Singapore Liver Cancer Recurrence (SLICER) Score for relapse prediction in patients with surgically resected hepatocellular carcinoma. PLoS One. 2015;10:e0118658. [PMID: 25830231 DOI: 10.1371/journal.pone.0118658] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
92 Wang D, Bai N, Hu X, OuYang XW, Yao L, Tao Y, Wang Z. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ. 2019;7:e7132. [PMID: 31632844 DOI: 10.7717/peerj.7132] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
93 Tanaka S, Mogushi K, Yasen M, Ban D, Noguchi N, Irie T, Kudo A, Nakamura N, Tanaka H, Yamamoto M. Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study. Hepatology. 2011;54:1273-1281. [PMID: 22006857 DOI: 10.1002/hep.24536] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
94 Marshall A, Lukk M, Kutter C, Davies S, Alexander G, Odom DT. Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma marker. PLoS One. 2013;8:e59459. [PMID: 23527199 DOI: 10.1371/journal.pone.0059459] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.0] [Reference Citation Analysis]
95 Désert R, Nieto N, Musso O. Dimensions of hepatocellular carcinoma phenotypic diversity. World J Gastroenterol 2018;24:4536-47. [PMID: 30386103 DOI: 10.3748/wjg.v24.i40.4536] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
96 Nault JC, Galle PR, Marquardt JU. The role of molecular enrichment on future therapies in hepatocellular carcinoma. J Hepatol. 2018;69:237-247. [PMID: 29505843 DOI: 10.1016/j.jhep.2018.02.016] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
97 Gao HJ, Zhao MC, Zhang YJ, Zhou DS, Xu L, Li GB, Chen MS, Liu J. Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration. J Cancer Res Clin Oncol. 2015;141:1151-1162. [PMID: 25446815 DOI: 10.1007/s00432-014-1888-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
98 Li W, Lu J, Ma Z, Zhao J, Liu J. An Integrated Model Based on a Six-Gene Signature Predicts Overall Survival in Patients With Hepatocellular Carcinoma. Front Genet 2019;10:1323. [PMID: 32010188 DOI: 10.3389/fgene.2019.01323] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
99 Castelli G, Pelosi E, Testa U. Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. Cancers (Basel) 2017;9:E127. [PMID: 28930164 DOI: 10.3390/cancers9090127] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 11.8] [Reference Citation Analysis]
100 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1555] [Article Influence: 321.3] [Reference Citation Analysis]
101 Hamed O, Kimchi ET, Sehmbey M, Gusani NJ, Kaifi JT, Staveley-O’Carroll K. Impact of genetic targets on cancer therapy: hepatocellular cancer. Adv Exp Med Biol. 2013;779:67-90. [PMID: 23288636 DOI: 10.1007/978-1-4614-6176-0_4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
102 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 236] [Article Influence: 43.3] [Reference Citation Analysis]
103 Calderaro J, Couchy G, Imbeaud S, Amaddeo G, Letouzé E, Blanc JF, Laurent C, Hajji Y, Azoulay D, Bioulac-Sage P, Nault JC, Zucman-Rossi J. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 2017;67:727-38. [PMID: 28532995 DOI: 10.1016/j.jhep.2017.05.014] [Cited by in Crossref: 222] [Cited by in F6Publishing: 193] [Article Influence: 55.5] [Reference Citation Analysis]
104 Huang X, Xiang L, Liu W, Li M, Ren A, Chen Z, Zheng C, Chengcong C, Liu J, Yuan Y. Roles of diencephalon/mesencephalon homeobox 1 in the development and prognosis of hepatocellular carcinoma. Ann Hepatol 2021;24:100314. [PMID: 33524552 DOI: 10.1016/j.aohep.2021.100314] [Reference Citation Analysis]
105 Jung YK, Jang K, Paik SS, Kwon YJ, Kim HJ, Lee KG, Park HK, Choi D. Positive immunostaining of Sal-like protein 4 is associated with poor patient survival outcome in the large and undifferentiated Korean hepatocellular carcinoma. Ann Surg Treat Res 2016;91:23-8. [PMID: 27433461 DOI: 10.4174/astr.2016.91.1.23] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
106 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 248] [Article Influence: 30.3] [Reference Citation Analysis]
107 Shen Q, Eun JW, Lee K, Kim HS, Yang HD, Kim SY, Lee EK, Kim T, Kang K, Kim S, Min DH, Oh SN, Lee YJ, Moon H, Ro SW, Park WS, Lee JY, Nam SW. Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma. Hepatology 2018;67:1360-77. [PMID: 29059470 DOI: 10.1002/hep.29606] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 11.7] [Reference Citation Analysis]
108 Losic B, Craig AJ, Villacorta-Martin C, Martins-Filho SN, Akers N, Chen X, Ahsen ME, von Felden J, Labgaa I, DʹAvola D, Allette K, Lira SA, Furtado GC, Garcia-Lezana T, Restrepo P, Stueck A, Ward SC, Fiel MI, Hiotis SP, Gunasekaran G, Sia D, Schadt EE, Sebra R, Schwartz M, Llovet JM, Thung S, Stolovitzky G, Villanueva A. Intratumoral heterogeneity and clonal evolution in liver cancer. Nat Commun 2020;11:291. [PMID: 31941899 DOI: 10.1038/s41467-019-14050-z] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 68.0] [Reference Citation Analysis]
109 Tsunedomi R, Iizuka N, Yoshimura K, Iida M, Tsutsui M, Hashimoto N, Kanekiyo S, Sakamoto K, Tamesa T, Oka M. ABCB6 mRNA and DNA methylation levels serve as useful biomarkers for prediction of early intrahepatic recurrence of hepatitis C virus-related hepatocellular carcinoma. Int J Oncol. 2013;42:1551-1559. [PMID: 23483087 DOI: 10.3892/ijo.2013.1854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
110 Doyle A, Sherman M. Liver Biopsy for Hepatocellular Carcinoma (HCC): Should this be a Routine? Curr Hepatology Rep 2017;16:46-50. [DOI: 10.1007/s11901-017-0333-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
111 Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019;16:617-630. [PMID: 31371809 DOI: 10.1038/s41575-019-0179-x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 28.5] [Reference Citation Analysis]
112 Xu J, Ding T, He Q, Yu X, Wu W, Jia W, Yun J, Zhang Y, Shi M, Shao C, Pan W, Yin X, Min J, Zhuang S, Zheng L. An in situ molecular signature to predict early recurrence in hepatitis B virus-related hepatocellular carcinoma. Journal of Hepatology 2012;57:313-21. [DOI: 10.1016/j.jhep.2012.03.027] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
113 Burak KW, Sherman M. Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol. 2015;29:178-184. [PMID: 25965437 DOI: 10.1155/2015/824263] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
114 Bittermann T, Hoteit MA, Abt PL, Forde KA, Goldberg D. Waiting Time and Explant Pathology in Transplant Recipients With Hepatocellular Carcinoma: A Novel Study Using National Data: Waiting Time and HCC Pathology. American Journal of Transplantation 2014;14:1657-63. [DOI: 10.1111/ajt.12774] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
115 Poté N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, Puy H, Bedossa P, Paradis V. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62:848-854. [PMID: 25450201 DOI: 10.1016/j.jhep.2014.11.005] [Cited by in Crossref: 117] [Cited by in F6Publishing: 117] [Article Influence: 16.7] [Reference Citation Analysis]
116 Xu H, Moni MA, Liò P. Network regularised Cox regression and multiplex network models to predict disease comorbidities and survival of cancer. Computational Biology and Chemistry 2015;59:15-31. [DOI: 10.1016/j.compbiolchem.2015.08.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
117 Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabró R, Pinyol R, Torres-Martin M, Bassaganyas L, Moeini A, Peix J, Cabellos L, Maeda M, Villacorta-Martin C, Tabrizian P, Rodriguez-Carunchio L, Castellano G, Sempoux C, Minguez B, Pawlik TM, Labgaa I, Roberts LR, Sole M, Fiel MI, Thung S, Fuster J, Roayaie S, Villanueva A, Schwartz M, Llovet JM. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol 2020;73:315-27. [PMID: 32173382 DOI: 10.1016/j.jhep.2020.03.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 29.0] [Reference Citation Analysis]
118 van Malenstein H, Komuta M, Verslype C, Vandecaveye V, Van Calster B, Topal B, Laleman W, Cassiman D, Van Steenbergen W, Aerts R. Histology obtained by needle biopsy gives additional information on the prognosis of hepatocellular carcinoma. Hepatol Res. 2012;42:990-998. [PMID: 22548688 DOI: 10.1111/j.1872-034x.2012.01010.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
119 Nault JC, Villanueva A. Biomarkers for Hepatobiliary Cancers. Hepatology. 2021;73 Suppl 1:115-127. [PMID: 32045030 DOI: 10.1002/hep.31175] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
120 Huang Z, Liang B, Xiong M, Dong K, Zhang Z, Zhang E, Li C, Chen X. Severity of cirrhosis should determine the operative modality for patients with early hepatocellular carcinoma and compensated liver function. Surgery 2016;159:621-31. [DOI: 10.1016/j.surg.2015.09.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
121 Labgaa I, Villanueva A, Dormond O, Demartines N, Melloul E. The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication. Cancers (Basel) 2021;13:659. [PMID: 33562173 DOI: 10.3390/cancers13040659] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
122 Gehrau R, Mas V, Archer KJ, Maluf D. Molecular classification and clonal differentiation of hepatocellular carcinoma: the step forward for patient selection for liver transplantation. Expert Rev Gastroenterol Hepatol. 2011;5:539-552. [PMID: 21780900 DOI: 10.1586/egh.11.48] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
123 Dekervel J, Popovic D, van Malenstein H, Windmolders P, Heylen L, Libbrecht L, Bulle A, De Moor B, Van Cutsem E, Nevens F, Verslype C, van Pelt J. A Global Risk Score (GRS) to Simultaneously Predict Early and Late Tumor Recurrence Risk after Resection of Hepatocellular Carcinoma. Transl Oncol 2016;9:139-46. [PMID: 27084430 DOI: 10.1016/j.tranon.2016.02.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
124 Yang J, Sheng YY, Wei JW, Gao XM, Zhu Y, Jia HL, Dong QZ, Qin LX. MicroRNA-219-5p Promotes Tumor Growth and Metastasis of Hepatocellular Carcinoma by Regulating Cadherin 1. Biomed Res Int 2018;2018:4793971. [PMID: 29862272 DOI: 10.1155/2018/4793971] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
125 Ding Y, Sun Z, Zhang S, Li Y, Han X, Xu Q, Zhou L, Xu H, Bai Y, Xu C, Ding H, Ge Y, Wang W. Downregulation of snoRNA SNORA52 and Its Clinical Significance in Hepatocellular Carcinoma. Biomed Res Int 2021;2021:7020637. [PMID: 34195281 DOI: 10.1155/2021/7020637] [Reference Citation Analysis]
126 Mahoney DW, Therneau TM, Anderson SK, Jen J, Kocher JP, Reinholz MM, Perez EA, Eckel-Passow JE. Quality assessment metrics for whole genome gene expression profiling of paraffin embedded samples. BMC Res Notes 2013;6:33. [PMID: 23360712 DOI: 10.1186/1756-0500-6-33] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
127 Kong J, Wang T, Zhang Z, Yang X, Shen S, Wang W. Five Core Genes Related to the Progression and Prognosis of Hepatocellular Carcinoma Identified by Analysis of a Coexpression Network. DNA Cell Biol 2019;38:1564-76. [PMID: 31633379 DOI: 10.1089/dna.2019.4932] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
128 Peveling-oberhag J, Döring C, Hartmann S, Filmann N, Mertens A, Piiper A, Herrmann E, Hansmann M, Zeuzem S, Trojan J, Welker M. Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib. Clinical Science 2015;128:29-37. [DOI: 10.1042/cs20140007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Méndez-González J, Imbeaud S, Letouzé E, Hernandez-Gea V, Cornella H. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology. 2015;61:1945-1956. [PMID: 25645722 DOI: 10.1002/hep.27732] [Cited by in Crossref: 197] [Cited by in F6Publishing: 168] [Article Influence: 32.8] [Reference Citation Analysis]
130 Jeong WK, Jamshidi N, Felker ER, Raman SS, Lu DS. Radiomics and radiogenomics of primary liver cancers. Clin Mol Hepatol 2019;25:21-9. [PMID: 30441889 DOI: 10.3350/cmh.2018.1007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
131 Wang J, Xia C, Pu M, Dai B, Yang X, Shang R, Yang Z, Zhang R, Tao K, Dou K. Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma. Oncol Rep 2018;40:1875-84. [PMID: 30015982 DOI: 10.3892/or.2018.6579] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
132 Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. European Journal of Cancer 2012;48:1977-87. [DOI: 10.1016/j.ejca.2012.01.015] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 7.1] [Reference Citation Analysis]
133 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 289] [Article Influence: 31.0] [Reference Citation Analysis]
134 Taouli B, Hoshida Y, Kakite S, Chen X, Tan PS, Sun X, Kihira S, Kojima K, Toffanin S, Fiel MI, Hirschfield H, Wagner M, Llovet JM. Imaging-based surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results. Eur Radiol. 2017;27:4472-4481. [PMID: 28439654 DOI: 10.1007/s00330-017-4844-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
135 Teufel A, Marquardt JU, Staib F, Galle PR. Snapshot liver transcriptome in hepatocellular carcinoma. Journal of Hepatology 2012;56:990-2. [DOI: 10.1016/j.jhep.2011.08.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
136 Nault JC, De Reyniès A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013;145:176-187. [PMID: 23567350 DOI: 10.1053/j.gastro.2013.03.051] [Cited by in Crossref: 226] [Cited by in F6Publishing: 192] [Article Influence: 28.3] [Reference Citation Analysis]
137 Goossens N, Sun X, Hoshida Y. Molecular classification of hepatocellular carcinoma: potential therapeutic implications. Hepat Oncol 2015;2:371-9. [PMID: 26617981 DOI: 10.2217/hep.15.26] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 10.5] [Reference Citation Analysis]
138 Calderaro J, Nault JC, Bioulac-Sage P, Laurent A, Blanc JF, Decaens T, Zucman-Rossi J. ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ß-catenin pathway. Virchows Arch 2014;464:53-60. [PMID: 24276407 DOI: 10.1007/s00428-013-1515-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
139 Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao K, Villanueva A, Thung SN, Schwartz ME, Llovet JM. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 2017;66:952-61. [PMID: 28126467 DOI: 10.1016/j.jhep.2017.01.010] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 17.5] [Reference Citation Analysis]
140 Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci 2018;5:181006. [PMID: 30662724 DOI: 10.1098/rsos.181006] [Cited by in Crossref: 124] [Cited by in F6Publishing: 120] [Article Influence: 41.3] [Reference Citation Analysis]
141 Miltiadous O, Sia D, Hoshida Y, Fiel MI, Harrington AN, Thung SN, Tan PS, Dong H, Revill K, Chang CY, Roayaie S, Byrne TJ, Mazzaferro V, Rakela J, Florman S, Schwartz M, Llovet JM. Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation. Journal of Hepatology 2015;63:1368-77. [DOI: 10.1016/j.jhep.2015.07.025] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
142 Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2013;10:34-42. [PMID: 23147664 DOI: 10.1038/nrgastro.2012.199] [Cited by in Crossref: 210] [Cited by in F6Publishing: 196] [Article Influence: 23.3] [Reference Citation Analysis]
143 Yang HD, Eun JW, Lee KB, Shen Q, Kim HS, Kim SY, Seo DW, Park WS, Lee JY, Nam SW. T-cell immune regulator 1 enhances metastasis in hepatocellular carcinoma. Exp Mol Med 2018;50:e420. [PMID: 29303507 DOI: 10.1038/emm.2017.166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
144 Alsinet C, Villanueva A, Llovet JM. Cell population genetics and deep sequencing: A novel approach for drivers discovery in hepatocellular carcinoma. Journal of Hepatology 2012;56:1198-200. [DOI: 10.1016/j.jhep.2011.11.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
145 Buendia MA, Bourre L, Cairo S. Myc target miRs and liver cancer: small molecules to get Myc sick. Gastroenterology. 2012;142:214-218. [PMID: 22178210 DOI: 10.1053/j.gastro.2011.12.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
146 Lee SC, Tan HT, Chung MC. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. World J Gastroenterol. 2014;20:3112-3124. [PMID: 24696598 DOI: 10.3748/wjg.v20.i12.3112] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 52] [Article Influence: 8.8] [Reference Citation Analysis]
147 Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:139-152. [PMID: 31792430 DOI: 10.1038/s41575-019-0229-4] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 52.0] [Reference Citation Analysis]
148 Hernandez-Gea V, Turon F, Berzigotti A, Villanueva A. Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension. World J Gastroenterol. 2013;19:1193-1199. [PMID: 23482437 DOI: 10.3748/wjg.v19.i8.1193] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
149 Tao Y, Hu K, Tan F, Zhang S, Zhou M, Luo J, Wang Z. SH3-domain binding protein 1 in the tumor microenvironment promotes hepatocellular carcinoma metastasis through WAVE2 pathway. Oncotarget 2016;7:18356-70. [PMID: 26933917 DOI: 10.18632/oncotarget.7786] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
150 Hectors SJ, Wagner M, Bane O, Besa C, Lewis S, Remark R, Chen N, Fiel MI, Zhu H, Gnjatic S, Merad M, Hoshida Y, Taouli B. Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging. Sci Rep. 2017;7:2452. [PMID: 28550313 DOI: 10.1038/s41598-017-02706-z] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
151 Chen G, Dai ZK, Liang RG, Xiao SJ, He SQ, Zhao HL, Xu Q. Characterization of diethylnitrosamine-induced liver carcinogenesis in Syrian golden hamsters. Exp Ther Med 2012;3:285-92. [PMID: 22969883 DOI: 10.3892/etm.2011.406] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
152 Matthai SM, Ramakrishna B. Cancer stem cells in hepatocellular carcinoma--an immunohistochemical study with histopathological association. Indian J Med Res 2015;142:391-8. [PMID: 26609030 DOI: 10.4103/0971-5916.169195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
153 Sun HW, Yu XJ, Wu WC, Chen J, Shi M, Zheng L, Xu J. GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma. PLoS One 2016;11:e0168907. [PMID: 28036362 DOI: 10.1371/journal.pone.0168907] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
154 Gao H, Zhou X, Li H, Liu F, Zhu H, Song X, Niu Z, Ni Q, Yang C, Lu J. Role of Matrix Metallopeptidase 12 in the Development of Hepatocellular Carcinoma. Journal of Investigative Surgery 2021;34:366-72. [DOI: 10.1080/08941939.2019.1637975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
155 Xu M, Zhen L, Lin L, Wu K, Wang Y, Cai X. Overexpression of CSN6 promotes the epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2020;44:340-8. [PMID: 31422034 DOI: 10.1016/j.clinre.2019.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
156 Yokomichi N, Nishida N, Umeda Y, Taniguchi F, Yasui K, Toshima T, Mori Y, Nyuya A, Tanaka T, Yamada T, Yagi T, Fujiwara T, Yamaguchi Y, Goel A, Kudo M, Nagasaka T. Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency. Liver Cancer 2019;8:239-54. [PMID: 31602368 DOI: 10.1159/000490806] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
157 Yamashita T, Koshikawa N, Shimakami T, Terashima T, Nakagawa M, Nio K, Horii R, Iida N, Kawaguchi K, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kitao A, Kobayashi S, Takahara S, Imai Y, Yoshimura K, Murayama T, Nakamoto Y, Yoshida E, Yoshimura T, Seiki M, Kaneko S. Serum Laminin γ2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma. Hepatology 2021;74:760-75. [PMID: 33609304 DOI: 10.1002/hep.31758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
158 Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. Transpl Int. 2013;26:109-118. [PMID: 22994652 DOI: 10.1111/j.1432-2277.2012.01562.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 10.0] [Reference Citation Analysis]
159 Wu Y, Liu Z, Xu X. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Commun (Lond) 2020;40:681-93. [PMID: 33290597 DOI: 10.1002/cac2.12115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
160 Pan L, Fang J, Chen MY, Zhai ST, Zhang B, Jiang ZY, Juengpanich S, Wang YF, Cai XJ. Promising key genes associated with tumor microenvironments and prognosis of hepatocellular carcinoma. World J Gastroenterol 2020;26:789-803. [PMID: 32148377 DOI: 10.3748/wjg.v26.i8.789] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
161 Ziol M, Sutton A, Calderaro J, Barget N, Aout M, Leroy V, Blanc J, Sturm N, Bioulac-sage P, Nahon P, Nault J, Charnaux N, N’kontchou G, Trinchet J, Delehedde M, Seror O, Beaugrand M, Vicaut E, Ganne-carrié N. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. Journal of Hepatology 2013;59:1264-70. [DOI: 10.1016/j.jhep.2013.07.030] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
162 Du Y, Han X, Ding YB, Yin JH, Cao GW. Prediction and prophylaxis of hepatocellular carcinoma occurrence and postoperative recurrence in chronic hepatitis B virus-infected subjects. World J Gastroenterol 2016;22:6565-72. [PMID: 27547000 DOI: 10.3748/wjg.v22.i29.6565] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
163 Effendi K, Yamazaki K, Fukuma M, Sakamoto M. Overexpression of Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5 (LGR5) Represents a Typical Wnt/β-Catenin Pathway-Activated Hepatocellular Carcinoma. Liver Cancer 2014;3:451-7. [PMID: 26280006 DOI: 10.1159/000343873] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
164 Shan Q, Kuang S, Zhang Y, He B, Wu J, Zhang T, Wang J. A comparative study of monoexponential versus biexponential models of diffusion-weighted imaging in differentiating histologic grades of hepatitis B virus-related hepatocellular carcinoma. Abdom Radiol (NY) 2020;45:90-100. [PMID: 31595327 DOI: 10.1007/s00261-019-02253-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Ingrisch M, Schneider MJ, Nörenberg D, Negrao de Figueiredo G, Maier-Hein K, Suchorska B, Schüller U, Albert N, Brückmann H, Reiser M, Tonn JC, Ertl-Wagner B. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma. Invest Radiol 2017;52:360-6. [PMID: 28079702 DOI: 10.1097/RLI.0000000000000349] [Cited by in Crossref: 62] [Cited by in F6Publishing: 26] [Article Influence: 20.7] [Reference Citation Analysis]
166 Shan S, Chen W, Jia JD. Transcriptome Analysis Revealed a Highly Connected Gene Module Associated With Cirrhosis to Hepatocellular Carcinoma Development. Front Genet 2019;10:305. [PMID: 31001331 DOI: 10.3389/fgene.2019.00305] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
167 Calderaro J, Ziol M, Paradis V, Zucman-rossi J. Molecular and histological correlations in liver cancer. Journal of Hepatology 2019;71:616-30. [DOI: 10.1016/j.jhep.2019.06.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 61] [Article Influence: 37.0] [Reference Citation Analysis]
168 Hoshida Y, Moeini A, Alsinet C, Kojima K, Villanueva A. Gene Signatures in the Management of Hepatocellular Carcinoma. Seminars in Oncology 2012;39:473-85. [DOI: 10.1053/j.seminoncol.2012.05.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
169 Zhu W, Xu J, Chen Z, Jiang J. Analyzing Roles of NUSAP1 From Clinical, Molecular Mechanism and Immune Perspectives in Hepatocellular Carcinoma. Front Genet 2021;12:689159. [PMID: 34354737 DOI: 10.3389/fgene.2021.689159] [Reference Citation Analysis]
170 Dhanasekaran R, Nault JC, Roberts LR, Zucman-Rossi J. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology 2019;156:492-509. [PMID: 30404026 DOI: 10.1053/j.gastro.2018.11.001] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 21.7] [Reference Citation Analysis]
171 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014;20:5935-50. [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 84] [Article Influence: 13.7] [Reference Citation Analysis]
172 Nahm JH, Rhee H, Kim H, Yoo JE, San Lee J, Jeon Y, Choi GH, Park YN. Increased expression of stemness markers and altered tumor stroma in hepatocellular carcinoma under TACE-induced hypoxia: A biopsy and resection matched study. Oncotarget. 2017;8:99359-99371. [PMID: 29245907 DOI: 10.18632/oncotarget.22078] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
173 Yang PC, Ho CM, Hu RH, Ho MC, Wu YM, Lee PH. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma. World J Hepatol 2016;8:1309-17. [PMID: 27872682 DOI: 10.4254/wjh.v8.i31.1309] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
174 Chen HA, Kuo TC, Tseng CF, Ma JT, Yang ST, Yen CJ, Yang CY, Sung SY, Su JL. Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma. Hepatology. 2016;64:1637-1651. [PMID: 27530187 DOI: 10.1002/hep.28773] [Cited by in Crossref: 45] [Cited by in F6Publishing: 52] [Article Influence: 9.0] [Reference Citation Analysis]
175 Lo RC, Ng IO. Hepatocellular tumors: immunohistochemical analyses for classification and prognostication. Chin J Cancer Res. 2011;23:245-253. [PMID: 23359751 DOI: 10.1007/s11670-011-0245-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
176 Shang Y, Zhang X, Zhou X, Wang J. Extracellular volume fraction measurements derived from the longitudinal relaxation of blood-based synthetic hematocrit may lead to clinical errors in 3 T cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2018;20:56. [PMID: 30089499 DOI: 10.1186/s12968-018-0475-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
177 Xu J, Li X, Yang H, Chang R, Kong C, Yang L. SIN1 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition: SIN1 Promotes Invasion of HCC. Cancer 2013;119:2247-57. [DOI: 10.1002/cncr.28023] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
178 Cai J, Li B, Zhu Y, Fang X, Zhu M, Wang M, Liu S, Jiang X, Zheng J, Zhang X, Chen P. Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties. EBioMedicine 2017;19:18-30. [PMID: 28434945 DOI: 10.1016/j.ebiom.2017.04.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
179 Martinez-Garcia R, Juan D, Rausell A, Muñoz M, Baños N, Menéndez C, Lopez-Casas PP, Rico D, Valencia A, Hidalgo M. Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med 2014;6:27. [PMID: 24739241 DOI: 10.1186/gm544] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
180 Mah WC, Lee CG. DNA methylation: potential biomarker in Hepatocellular Carcinoma. Biomark Res. 2014;2:5. [PMID: 24635883 DOI: 10.1186/2050-7771-2-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
181 Nault JC. Pathogenesis of hepatocellular carcinoma according to aetiology. Best Pract Res Clin Gastroenterol. 2014;28:937-947. [PMID: 25260319 DOI: 10.1016/j.bpg.2014.08.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
182 Ramzan M, Sturm N, Decaens T, Bioulac-Sage P, Bancel B, Merle P, Tran Van Nhieu J, Slama R, Letoublon C, Zarski JP. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma. Liver Int. 2016;36:434-444. [PMID: 26215124 DOI: 10.1111/liv.12927] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
183 Hernandez C, Huebener P, Pradere JP, Antoine DJ, Friedman RA, Schwabe RF. HMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis. J Clin Invest 2018;128:2436-51. [PMID: 29558367 DOI: 10.1172/JCI91786] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
184 Wang J, Li H, Xia C, Yang X, Dai B, Tao K, Dou K. Downregulation of CENPK suppresses hepatocellular carcinoma malignant progression through regulating YAP1. Onco Targets Ther 2019;12:869-82. [PMID: 30774374 DOI: 10.2147/OTT.S190061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
185 Takamatsu FY, Gonzalez AM, Sá GP, Salzedas-Netto AA. Transplantation in Hepatocellular Carcinoma: Observational Multivariate Analysis of Survival and Recurrence Factors in 414 Patients. Transplant Proc 2021;53:1957-61. [PMID: 34229903 DOI: 10.1016/j.transproceed.2021.06.002] [Reference Citation Analysis]
186 OuYang HY, Xu J, Luo J, Zou RH, Chen K, Le Y, Zhang YF, Wei W, Guo RP, Shi M. MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma. Hepatology. 2016;63:1227-1239. [PMID: 26660154 DOI: 10.1002/hep.28397] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
187 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1628] [Article Influence: 707.3] [Reference Citation Analysis]
188 Ella E, Heim D, Stoyanov E, Harari-Steinfeld R, Steinfeld I, Pappo O, Perlman TS, Nachmansson N, Rivkin L, Olam D, Abramovitch R, Wege H, Galun E, Goldenberg D. Specific genomic and transcriptomic aberrations in tumors induced by partial hepatectomy of a chronically inflamed murine liver. Oncotarget 2014;5:10318-31. [PMID: 25401338 DOI: 10.18632/oncotarget.2515] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
189 Lu YY, Chen QL, Guan Y, Guo ZZ, Zhang H, Zhang W, Hu YY, Su SB. Transcriptional profiling and co-expression network analysis identifies potential biomarkers to differentiate chronic hepatitis B and the caused cirrhosis. Mol Biosyst 2014;10:1117-25. [PMID: 24599568 DOI: 10.1039/c3mb70474b] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
190 Liu TC, Vachharajani N, Chapman WC, Brunt EM. SALL4 immunoreactivity predicts prognosis in Western hepatocellular carcinoma patients but is a rare event: a study of 236 cases. Am J Surg Pathol 2014;38:966-72. [PMID: 24805857 DOI: 10.1097/PAS.0000000000000218] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 3.9] [Reference Citation Analysis]
191 Seino S, Tsuchiya A, Watanabe Y, Kawata Y, Kojima Y, Ikarashi S, Yanai H, Nakamura K, Kumaki D, Hirano M, Funakoshi K, Aono T, Sakai T, Sakata J, Takamura M, Kawai H, Yamagiwa S, Wakai T, Terai S. Clinical outcome of hepatocellular carcinoma can be predicted by the expression of hepatic progenitor cell markers and serum tumour markers. Oncotarget 2018;9:21844-60. [PMID: 29774107 DOI: 10.18632/oncotarget.25074] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
192 Désert R, Rohart F, Canal F, Sicard M, Desille M, Renaud S, Turlin B, Bellaud P, Perret C, Clément B, Lê Cao KA, Musso O. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology 2017;66:1502-18. [PMID: 28498607 DOI: 10.1002/hep.29254] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 9.8] [Reference Citation Analysis]
193 Felipe-Silva A, Wakamatsu A, Dos Santos Cirqueira C, Alves VA. Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases. World J Gastroenterol 2016;22:6246-56. [PMID: 27468214 DOI: 10.3748/wjg.v22.i27.6246] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
194 Izumi N. Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma. Hepatol Res. 2012;42:226-232. [PMID: 22181559 DOI: 10.1111/j.1872-034x.2011.00922.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
195 Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson RT, Lachenmayer A, Revill K, Alsinet C, Sachidanandam R, Desai A, SenBanerjee S, Ukomadu C, Llovet JM, Sadler KC. UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell. 2014;25:196-209. [PMID: 24486181 DOI: 10.1016/j.ccr.2014.01.003] [Cited by in Crossref: 184] [Cited by in F6Publishing: 165] [Article Influence: 26.3] [Reference Citation Analysis]
196 Li F, Qiao CY, Gao S, Fan YC, Chen LY, Wang K. Circulating cell-free DNA of methylated insulin-like growth factor-binding protein 7 predicts a poor prognosis in hepatitis B virus-associated hepatocellular carcinoma after hepatectomy. Free Radic Res 2018;52:455-64. [PMID: 29463155 DOI: 10.1080/10715762.2018.1443448] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
197 Gan X, Luo Y, Dai G, Lin J, Liu X, Zhang X, Li A. Identification of Gene Signatures for Diagnosis and Prognosis of Hepatocellular Carcinomas Patients at Early Stage. Front Genet 2020;11:857. [PMID: 32849835 DOI: 10.3389/fgene.2020.00857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
198 Wang S, Shen HW, Chai H, Liang Y. Complex harmonic regularization with differential evolution in a memetic framework for biomarker selection. PLoS One 2019;14:e0210786. [PMID: 30763332 DOI: 10.1371/journal.pone.0210786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
199 Li L, Guo L, Wang Q, Liu X, Zeng Y, Wen Q, Zhang S, Kwok HF, Lin Y, Liu J. DAPK1 as an independent prognostic marker in liver cancer. PeerJ 2017;5:e3568. [PMID: 28740751 DOI: 10.7717/peerj.3568] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
200 Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012;10:354-362. [PMID: 22083023 DOI: 10.1016/j.cgh.2011.11.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
201 Marquardt JU, Galle PR, Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J Hepatol. 2012;56:267-275. [PMID: 21782758 DOI: 10.1016/j.jhep.2011.07.007] [Cited by in Crossref: 117] [Cited by in F6Publishing: 105] [Article Influence: 11.7] [Reference Citation Analysis]
202 Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut 2019;68:1065-75. [PMID: 30108162 DOI: 10.1136/gutjnl-2018-316408] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 24.7] [Reference Citation Analysis]
203 Eghtesad B, Aucejo F. Liver transplantation for malignancies. J Gastrointest Cancer. 2014;45:353-362. [PMID: 24604263 DOI: 10.1007/s12029-014-9590-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
204 Gonzalez SA. Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived? Hepatobiliary Surg Nutr. 2014;3:410-414. [PMID: 25568864 DOI: 10.3978/j.issn.2304-3881.2014.07.06] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
205 Gao F, Zhu HK, Zhu YB, Shan QN, Ling Q, Wei XY, Xie HY, Zhou L, Xu X, Zheng SS. Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern. Hepatobiliary Pancreat Dis Int 2016;15:371-7. [PMID: 27498576 DOI: 10.1016/s1499-3872(16)60095-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
206 Erstad DJ, Fuchs BC, Tanabe KK. Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. Cancer 2018;124:3084-104. [DOI: 10.1002/cncr.31257] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
207 Yu JX, Craig AJ, Duffy ME, Villacorta-Martin C, Miguela V, Ruiz de Galarreta M, Scopton AP, Silber L, Maldonado AY, Rialdi A, Guccione E, Lujambio A, Villanueva A, Dar AC. Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology. Mol Cancer Ther 2019;18:1506-19. [PMID: 31213506 DOI: 10.1158/1535-7163.MCT-18-0571] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
208 Yu Y, Yang J, Li Q, Xu B, Lian Y, Miao L. LINC00152: A pivotal oncogenic long non-coding RNA in human cancers. Cell Prolif 2017;50. [PMID: 28464433 DOI: 10.1111/cpr.12349] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
209 Nault JC. Molecular Determinants of Prognosis in Hepatocellular Carcinoma. J Clin Transl Hepatol 2014;2:31-6. [PMID: 26357615 DOI: 10.14218/JCTH.2013.00029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
210 Piñero F, Tisi Baña M, de Ataide EC, Hoyos Duque S, Marciano S, Varón A, Anders M, Zerega A, Menéndez J, Zapata R, Muñoz L, Padilla Machaca M, Soza A, McCormack L, Poniachik J, Podestá LG, Gadano A, Boin IS, Duvoux C, Silva M; Latin American Liver Research, Education and Awareness Network (LALREAN). Liver transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. Liver Int 2016;36:1657-67. [PMID: 27169841 DOI: 10.1111/liv.13159] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
211 Virzì A, Roca Suarez AA, Baumert TF, Lupberger J. Rewiring Host Signaling: Hepatitis C Virus in Liver Pathogenesis. Cold Spring Harb Perspect Med 2020;10:a037366. [PMID: 31501266 DOI: 10.1101/cshperspect.a037366] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
212 He MK, Le Y, Zhang YF, Ouyang HY, Jian PE, Yu ZS, Wang LJ, Shi M. Matrix metalloproteinase 12 expression is associated with tumor FOXP3+ regulatory T cell infiltration and poor prognosis in hepatocellular carcinoma. Oncol Lett 2018;16:475-82. [PMID: 29928435 DOI: 10.3892/ol.2018.8642] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
213 Hectors SJ, Lewis S, Besa C, King MJ, Said D, Putra J, Ward S, Higashi T, Thung S, Yao S, Laface I, Schwartz M, Gnjatic S, Merad M, Hoshida Y, Taouli B. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur Radiol. 2020;30:3759-3769. [PMID: 32086577 DOI: 10.1007/s00330-020-06675-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
214 von Felden J, Villanueva A. Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2020;26:823-31. [PMID: 32061009 DOI: 10.1002/lt.25731] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
215 Yegin EG, Oymaci E, Karatay E, Coker A. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. Hepatobiliary & Pancreatic Diseases International 2016;15:234-56. [DOI: 10.1016/s1499-3872(16)60097-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 5.2] [Reference Citation Analysis]
216 Marshall A, Alexander G. Vascular invasion leaves its mark in hepatocellular carcinoma. J Hepatol 2011;55:1174-5. [PMID: 21703166 DOI: 10.1016/j.jhep.2011.05.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
217 Nault JC, Zucman-Rossi J. Genotype-phenotype relationships in hepatocellular carcinoma: p53 inactivation promotes tumors with stem cell features. Gastroenterology 2012;142:1066-9. [PMID: 22449579 DOI: 10.1053/j.gastro.2012.03.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
218 Zhang J, Huang T, Zhang F, Xu J, Chen G, Wang X, Huang L, Peng Z. Prognostic role of serum carbohydrate antigen 19-9 levels in patients with resectable hepatocellular carcinoma. Tumour Biol 2015;36:2257-61. [PMID: 25787748 DOI: 10.1007/s13277-014-2435-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
219 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
220 Zucman-rossi J, Villanueva A, Nault J, Llovet JM. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 2015;149:1226-1239.e4. [DOI: 10.1053/j.gastro.2015.05.061] [Cited by in Crossref: 531] [Cited by in F6Publishing: 469] [Article Influence: 88.5] [Reference Citation Analysis]
221 Caruso S, O’brien DR, Cleary SP, Roberts LR, Zucman‐rossi J. Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity. Hepatology 2021;73:14-26. [DOI: 10.1002/hep.31394] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 18.0] [Reference Citation Analysis]
222 Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: Approaching a personalized care. J Hepatol 2015;62:S144-56. [PMID: 25920083 DOI: 10.1016/j.jhep.2015.02.007] [Cited by in Crossref: 136] [Cited by in F6Publishing: 121] [Article Influence: 27.2] [Reference Citation Analysis]
223 Huang JF, Yeh ML, Yu ML, Dai CY, Huang CF, Huang CI, Tsai PC, Lin PC, Chen YL, Chang WT, Hou NJ, Lin ZY, Chen SC, Chuang WL. The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. J Gastroenterol Hepatol 2015;30:1768-74. [PMID: 26094738 DOI: 10.1111/jgh.13012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
224 Anfuso B, El-Khobar KE, Sukowati CH, Tiribelli C. The multiple origin of cancer stem cells in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2015;39 Suppl 1:S92-S97. [PMID: 26186879 DOI: 10.1016/j.clinre.2015.05.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
225 Ramos LA, van der Steen WE, Sales Barros R, Majoie CBLM, van den Berg R, Verbaan D, Vandertop WP, Zijlstra IJAJ, Zwinderman AH, Strijkers GJ, Olabarriaga SD, Marquering HA. Machine learning improves prediction of delayed cerebral ischemia in patients with subarachnoid hemorrhage. J NeuroIntervent Surg 2019;11:497-502. [DOI: 10.1136/neurintsurg-2018-014258] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
226 Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault JC, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Llovet JM, Villanueva A. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology 2021;160:2572-84. [PMID: 33705745 DOI: 10.1053/j.gastro.2021.01.233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
227 King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan PS, Sun X. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut. 2015;64:1296-1302. [PMID: 25143343 DOI: 10.1136/gutjnl-2014-307862] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
228 Kim SU, Jung KS, Lee S, Park JY, Kim do Y, Ahn SH, Choi GH, Kim KS, Choi JS, Han KH. Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma. Liver Int. 2014;34:1008-1017. [PMID: 24483989 DOI: 10.1111/liv.12475] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
229 Quetglas IM, Moeini A, Pinyol R, Llovet JM. Integration of genomic information in the clinical management of HCC. Best Pract Res Clin Gastroenterol 2014;28:831-42. [PMID: 25260311 DOI: 10.1016/j.bpg.2014.08.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
230 Waldron L, Ogino S, Hoshida Y, Shima K, McCart Reed AE, Simpson PT, Baba Y, Nosho K, Segata N, Vargas AC, Cummings MC, Lakhani SR, Kirkner GJ, Giovannucci E, Quackenbush J, Golub TR, Fuchs CS, Parmigiani G, Huttenhower C. Expression profiling of archival tumors for long-term health studies. Clin Cancer Res 2012;18:6136-46. [PMID: 23136189 DOI: 10.1158/1078-0432.CCR-12-1915] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
231 Villanueva A, Luedde T. The transition from inflammation to cancer in the liver. Clin Liver Dis (Hoboken) 2016;8:89-93. [PMID: 31041071 DOI: 10.1002/cld.578] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
232 Zeng L, Yu J, Huang T, Jia H, Dong Q, He F, Yuan W, Qin L, Li Y, Xie L. Differential combinatorial regulatory network analysis related to venous metastasis of hepatocellular carcinoma. BMC Genomics 2012;13 Suppl 8:S14. [PMID: 23282077 DOI: 10.1186/1471-2164-13-S8-S14] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
233 Li R, Shui L, Jia J, Wu C. Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma. Front Genet 2020;11:906. [PMID: 32922438 DOI: 10.3389/fgene.2020.00906] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
234 Breuker C, Planque C, Rajabi F, Nault JC, Couchy G, Zucman-Rossi J, Evrard A, Kantar J, Chevet E, Bioulac-Sage P, Ramos J, Assenat E, Joubert D, Pannequin J, Hollande F, Pascussi JM. Characterization of a novel PXR isoform with potential dominant-negative properties. J Hepatol 2014;61:609-16. [PMID: 24798619 DOI: 10.1016/j.jhep.2014.04.030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
235 Tanabe KK, Hoshida Y. Prognostic gene signatures for hepatocellular carcinoma: what are we measuring? Ann Surg Oncol 2013;20:3707-8. [PMID: 23797752 DOI: 10.1245/s10434-013-3071-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]